Latest Going Concern Risk News

Adisyn Ltd reported a sharp increase in losses for FY25, driven by a 40% revenue drop and a costly acquisition, while securing significant new equity funding.

Cann Group Limited reported a significant 56% reduction in net loss for FY25, driven by cost cuts and strong growth in dried flower sales, even as revenue declined due to shifting product preferences. The company faces going concern challenges but is actively pursuing debt refinancing and operational improvements.

Axiom Properties Limited reports a 55% reduction in net loss for FY25, completing its Glenlea Estate sales and accelerating its Property Technology strategy with a $30 million debt facility for PaySure.

The Hydration Pharmaceuticals Company Limited reported a 55% reduction in half-year losses to $1.44 million, driven by strategic cost reductions and a sharpened focus on US e-commerce operations. Despite a 15% revenue decline, the company is banking on new product launches and retail expansion to fuel growth.

Spacetalk Limited reported a 12.2% revenue increase to $19.6 million in FY25, driven by recurring mobile subscriptions and device sales, while reducing its net loss by 27.1%. The company secured $3 million in capital post-year-end to support growth amid ongoing going concern uncertainties.

Gale Pacific Limited reported a 1.1% revenue decline to $172 million and a significant net loss of $5.18 million for FY2025, accompanied by a cautious auditor's note on going concern.

Nutritional Growth Solutions reported a 30% drop in revenue to US$867k for H1 FY25 but narrowed its loss to US$1.2 million, driven by cost discipline and new retail partnerships including Walmart and CVS.

Gratifii Limited reported a substantial 82% increase in revenue for FY25, driven by key acquisitions, yet underlying losses widened due to integration and impairment costs. The company faces ongoing challenges despite top-line growth.

PARKD Limited reported a remarkable 218% increase in revenue to $11.83 million for FY25, driven by key construction projects and new licensing agreements. The company narrowed its loss by 74%, signaling progress in commercialising its modular construction technology.

PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.

Control Bionics Limited reported a 14.8% revenue increase to $6.14 million for FY2025 but also a 3.3% rise in net loss to $6.11 million, while pursuing a $2 million rights issue and expanding its investment portfolio.

RemSense Technologies posted a 107% revenue surge to $3.44 million in FY2025 alongside a 67% reduction in net loss, driven by operational efficiencies and strong client demand. The company achieved positive cash EBITDA and strengthened its global footprint with Tier 1 clients.